* Exclusive license for pending worldwide patents on therapeutics and diagnostics *


  • Stryka-Pro1 is a small extracellular matrix protein
  • Stryka-Pro1 can be produced as a recombinant protein in large quantities
  • Stryka-Pro1 increases α7β1 integrin and utrophin in DMD patient muscle cells
  • Stryka-Pro1 shows efficacy in preventing disease progression in preclinical models of muscular dystrophy

Small Molecule Therapeutics

  • Strykagen’s small molecules were identified using a novel α7β1 integrin muscle cell-based assay and by screening over 400,000 compounds using qHTS technology.
  • Stryka-516 and -969 have been shown to increase α7β1 integrin in DMD patient muscle cells.
  • Stryka-516 can be orally delivered and increases muscle strength in preclinical studies.
  • Strykagen’s small molecule therapeutics should be effective in treating DMD, MDC1A and LGMD2I and be independent of the site of the gene defect.
  • Stryakgen has the exclusive worldwide license to develop and market these small molecules and their derivatives for the treatment of muscular dystrophy.